Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 4 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

pembrolizumab 259Cyclophosphamide 242Specimen Handling 199fludarabine 174Magnetic Resonance Spectroscopy 174Biopsy 148Nivolumab 119Carboplatin 98Radiotherapy 92Paclitaxel 84venetoclax 82Cisplatin 81fludarabine phosphate 79Gemcitabine 79Injections 69Ipilimumab 63Dexamethasone 61atezolizumab 59Bevacizumab 59Cetuximab 57Azacitidine 56Radiation 55Fluorouracil 55durvalumab 54Radiosurgery 52Temozolomide 47Rituximab 44Oxaliplatin 44Irinotecan 43Docetaxel 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Quality of Life × 1 year × Clear all
NCT07340853 2026-03-10

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

University of California, San Francisco

Phase 1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡